A study to evaluate the safety, tolerability, and efficacy of galicaftor/navocaftor/ABBV-119 combination therapy in subjects with cystic fibrosis

Category Primary study
Registry of TrialsISRCTN registry
Year 2022
This article has no abstract
Epistemonikos ID: d2bc085b713b459daef7b7c0b7c8a3ca0c05d960
First added on: Mar 08, 2022